Indeed, this technology has enabled the correction of the multiple mutated genes associated with responding genetic disorders, including the DMD gene in DMD, CFTR gene in CF, factor IX gene in hemophilia B, hemoglobin beta-chain gene in β-thalassemia, presenilin 1 and 2 (PSEN1 and PSEN2) and apolipoprotein E4 (apoE4) genes in AD, HTT gene in HD, leucine-rich repeat kinase 2 (LRRKK2) gene in PD, fumarylacetoacetate hydrolase (FAH) in tyrosinemia, Hex gene in TSD, fragile X mental retardation 1 (FMR1) gene in FXS, etc. [90, 91]. The gene discussed is FAH; the disease is Duchenne muscular dystrophy.